Skip to main content
Clinical Trials/JPRN-UMIN000001583
JPRN-UMIN000001583
Completed
未知

Feasibility study of adjuvant chemotherapy consisting of FEC(fluoraouracil, epirubicin and cyclophosphamide) followed by DH(docetaxel+herceptin) for patients with HER2 positive breast cancer - Feasibility study of adjuvant chemotherapy consisting of FEC(fluoraouracil, epirubicin and cyclophosphamide) followed by DH(docetaxel+herceptin) for patients with HER2 positive breast cancer

Kyushu Breast Cancer Study Group0 sites45 target enrollmentDecember 17, 2008
ConditionsBreast cancer

Overview

Phase
未知
Intervention
Not specified
Conditions
Breast cancer
Sponsor
Kyushu Breast Cancer Study Group
Enrollment
45
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 17, 2008
End Date
December 1, 2011
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Kyushu Breast Cancer Study Group

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Clinical or radiological evidence of metastatic breast cancer 2\. complication of the active other malignancies 3\. Serious cardiac disfunction 4\. Uncontrolled medical conditions 5\. Significant interstitial pneumonia or pulmonary fibrosis by CT scan or X\-ray 6\. Patients who are required concurrent treatment by corticosteroids except for premedication 7 .Severe psychiatric disorders 8\. Pregnant or lactation women, or women with suspected pregnancy 9\. History of hypersensitivity reaction to drug formulated with Polysorbate 80 10\. Patients judged by the investigator to be unfit to be enrolled into the study

Outcomes

Primary Outcomes

Not specified

Similar Trials